Overview

Detailed Summary

Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients and operates through four divisions. It has five manufacturing facilities across India, enjoying numerous global certifications.
The company has a rich history of collaborations and initiatives, having set up various R&D centers and strategic plants since its inception in 1962, illustrating its commitment to growth and innovation.
Recent strategic moves include a significant acquisition by Ipca Laboratories Limited, which now holds majority control over Unichem, influencing its future trajectory and operational strategies.
Despite divesting some business components in the past, Unichem continues to expand its international presence, notably with a wholly owned subsidiary in China, reflecting its global ambitions.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Market Cap: 2,264 Cr
Volatility: High Risk
P/E Ratio: 7.7
Industry P/E: 27.5
PEG Ratio: 0.0
P/B Ratio: 0.9
52W High: 727.95
52W Low: 311.00

Sales CAGR

1Y: 18.25%
3Y: 22.56%
5Y: 13.92%
10Y: 3.84%

Profit CAGR

1Y: 246.67%
3Y: —
5Y: —
10Y: 5.52%

ROE

TTM: 5.98%
3Y: -2.16%
5Y: -0.73%
10Y: 11.57%

ROCE

TTM: 6.30%
3Y: -0.60%
5Y: 0.30%
10Y: -0.49%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
DCAL	164.50	2,574 Cr	21.73	0.40	0.00	2.14	3.12	1.07
NOVARTIND	920.55	2,273 Cr	23.37	2.93	2.71	13.75	17.93	10.43
UNICHEMLAB	320.00	2,264 Cr	7.66	0.93	0.00	5.98	6.30	8.29
MOREPENLAB	40.75	2,233 Cr	22.64	1.87	0.49	6.31	8.14	5.77
IOLCP	70.55	2,059 Cr	17.86	1.18	1.14	6.62	9.15	4.80
SOLARA	458.55	2,016 Cr	-95.38	1.34	0.00	0.51	5.47	-0.83
INDOCO	198.00	1,823 Cr	-15.70	1.86	0.10	-11.28	-2.11	-4.64

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	416	434	432	446	462	533	587	527	579	521
Expenses	407	396	406	403	405	448	503	504	513	476
Operating Profit	8.76	38	25	44	58	86	84	22	66	45
OPM %	2.11	8.78	5.87	9.74	12.45	16.04	14.25	4.27	11.43	8.59
Other Income	5.54	79	-119	3.86	8.79	14	9.25	6.82	-37	287
Interest	6.73	5.58	4.59	4.03	4.79	6.75	5.46	6.54	8.24	7.42
Depreciation	29	28	27	28	29	31	30	32	31	31
Profit Before Tax	-22	84	-126	15	33	62	58	-9.02	-11	293
Tax %	-11.93	-0.02	-2.73	38.27	7.58	6.47	8.36	-16.08	-9.89	9.93
Net Profit	-24	84	-129	9.26	30	58	53	-10	-12	264
EPS in Rs	-3.48	11.92	-18.36	1.31	4.32	8.19	7.50	-1.49	-1.69	37.47

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	699	815	1,180	1,104	1,235	1,270	1,343	1,705	2,111	2,109
Expenses	739	946	1,264	1,155	1,144	1,197	1,389	1,605	1,846	1,860
Operating Profit	-40	-131	-83	-51	91	73	-46	100	265	249
OPM %	-5.79	-16.14	-7.08	-4.60	7.38	5.73	-3.39	5.88	12.55	11.82
Other Income	5.69	61	98	92	50	46	-0.05	-26	35	38
Interest	3.36	8.01	7.52	7.85	5.12	6.11	17	23	21	24
Depreciation	44	51	67	82	84	91	113	113	125	121
Profit Before Tax	-83	-130	-60	-48	51	22	-176	-62	155	144
Tax %	14.35	-2.58	57.34	-24.83	33.32	-50.49	-14.67	-14.28	11.04	8.90
Net Profit	-71	-133	-26	-60	34	33	-202	-70	138	131
EPS in Rs	—	—	-4.26	-8.54	4.88	4.68	-28.72	-10.01	21.32	41.79
Dividend Payout %	25.13	1.78	-118.34	-46.78	81.97	85.47	-13.93	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	18	18	14	14	14	14	14	14	14	14
Reserves	936	1,045	2,666	2,606	2,517	2,543	2,604	2,421	2,348	2,437
Borrowings	36	98	151	200	207	119	349	314	248	460
Other Liabilities	293	365	363	330	407	450	351	444	559	659
Total Liabilities	1,284	1,527	3,194	3,150	3,145	3,126	3,319	3,193	3,169	3,569
Fixed Assets	403	487	574	806	866	880	990	1,257	1,196	1,300
CWIP	237	250	238	92	330	567	494	147	123	31
Investments	14	18	905	930	553	396	264	1.70	1.36	0.02
Other Assets	630	772	1,476	1,321	1,395	1,282	1,571	1,787	1,849	2,239
Total Assets	1,284	1,527	3,194	3,150	3,145	3,126	3,319	3,193	3,169	3,569

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	112	68	-112	-328	20	33	-260	-85	17	-7.02
Cash from Investing Activity	-85	-128	1,648	-286	-36	-66	102	239	50	-241
Cash from Financing Activity	-33	59	-881	-2.42	-62	-121	191	-81	-106	184
Net Cash Flow	-6.84	-0.46	655	-616	-78	-154	34	73	-39	-64

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	50.93%	50.93%	70.21%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%
FIIs	1.70%	1.62%	0.83%	0.84%	0.90%	0.89%	0.94%	1.06%	0.98%	0.98%	1.00%	0.99%
DIIs	8.16%	9.73%	10.32%	10.75%	11.27%	11.58%	11.67%	11.63%	11.32%	10.92%	10.75%	10.74%
Public	39.21%	37.72%	18.64%	18.18%	17.61%	17.30%	17.18%	17.09%	17.48%	17.88%	18.03%	18.05%
Total Shareholders	29,418	26,642	21,584	20,877	21,171	20,621	20,374	21,472	21,621	23,010	23,577	23,267

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY17

Investor Presentation

Q3 FY17

Investor Presentation

Q2 FY17

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q1 FY17

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q4 FY16

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY16

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Postal Ballot Notice

6 days ago

Unichem Laboratories publishes postal ballot notice (newspapers)

Unichem Laboratories Ltd informed exchanges under Regulation 30 that the Postal Ballot Notice and e‑voting details were published in Business Standard and Mumbai Lakshdeep on 26 Feb 2026 pursuant to Section 110 of the Companies Act, 2013.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Unichem Laboratories Ltd

Unichem Laboratories Ltd (UNICHEMLAB) is currently trading at 321.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients and operates through four divisions. It has five manufacturing facilities across India, enjoying numerous global certifications. The company has a rich history of collaborations and initiatives, having set up various R&D centers and strategic plants since its inception in 1962, illustrating its commitment to growth and innovation. Recent strategic moves include a significant acquisition by Ipca Laboratories Limited, which now holds majority control over Unichem, influencing its future trajectory and operational strategies. Despite divesting some business components in the past, Unichem continues to expand its international presence, notably with a wholly owned subsidiary in China, reflecting its global ambitions.

Over the past 52 weeks, Unichem Laboratories Ltd has traded between a low of ₹311.00 and a high of ₹727.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Unichem Laboratories Ltd has a market capitalization of approximately 2,263.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Unichem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.66 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,263.54 Cr, Unichem Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Unichem Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Unichem Laboratories Ltd is 7.66. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Unichem Laboratories Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison